This guide provides practical information that will assist clinicians involved in the diagnosis, assessment, treatment, and follow-up care of patients with triple-negative breast cancer. After opening chapters on the pathologic evaluation, clinical presentation, genetics, and imaging features, the full range of current treatment approaches is thoroughly reviewed from a multidisciplinary perspective. Readers will find up-to-date information and guidance on surgical management, radiation therapy, tailored adjuvant therapy, neoadjuvant treatment, systemic treatment for metastatic disease, molecular profiling, and targeted therapy. The coverage is completed by discussion of special issues in young women with triple-negative breast cancer and individualization of the management approach in older patients affected with the disease. All healthcare professionals who care for patients with triple-negative breast cancer will find the book to be an invaluable source of expert advice on the issues faced in real-world practice.

Antoinette R. Tan, MD, MHSc, FACP is the Chief of Breast Medical Oncology and Co-Director of the Phase I Program at Levine Cancer Institute, Carolinas HealthCare System. She is Section Chief of Hematology/Oncology at Carolinas HealthCare System Pineville and is also a Clinical Professor in the Department of Medicine at the University of North Carolina. Prior to joining Levine Cancer Institute, Dr. Tan was an Associate Professor of Medicine and the Director of Phase I and Investigational Therapeutics at Rutgers Cancer Institute of New Jersey. Dr. Tan's focus is on the clinical development of targeted treatments for triple-negative breast cancer. She has extensive experience in the conduct of early-phase clinical trials and breast cancer studies and has been the recipient of an NCI Cancer Clinical Investigator Team Leadership Award. She has been Principal Investigator for several trials focusing on the treatment of triple-negative breast cancer. Dr. Tan has served on the American Society of Clinical Oncology Education Program, as Chair and as a Breast Cancer Track Leader. She has also been actively involved in the clinical development of novel therapeutics, with leadership roles in the National Surgical Adjuvant Breast and Bowel Project (NSABP) and NRG Oncology. She has published many scientific papers and book chapters, and has served as a book editor.